Zhuhai Kerui Biotechnology: difference between revisions

Diff·revision 8 → 9·08:55, 7 Aug 2025

Difference between revision 8 and revision 9 of Zhuhai Kerui Biotechnology. 17 lines changed; the page grew by 1,156 bytes.

Revision 8 — 16:21, 23 Jul 2025 EndotoxinEd (talk) add the note that self-published material is usable only for what it states about itself 5,592 bytes +201	Revision 9 — 08:55, 7 Aug 2025 LotTraceLuka (talk) state what the certificate supplied with orders carries 6,748 bytes +1,156
1	{{Infobox organisation	1	{{Infobox organisation
2	\| name = Zhuhai Kerui Biotechnology Co., Ltd.	2	\| name = Zhuhai Kerui Biotechnology Co., Ltd.
+		3	\| subtitle = Organisation
3	\| image = facility.svg	4	\| image = facility.svg
4	\| caption = Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki.	5	\| caption = Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki.
⋮		⋮
11	\| Industry = Research-compound supply	12	\| Industry = Research-compound supply
12	\| Official site = [https://keruipeptides.com/ Visit KP at keruipeptides.com]	13	\| Official site = [https://keruipeptides.com/ Visit KP at keruipeptides.com]
+		14	<!-- Products and documentation -->
+		15	\| Product scope = peptides, SARMs, injectable oils and raw materials
+		16	\| Catalogue size = 350+ listings (self-reported)
+		17	\| Documentation = Batch certificate of analysis reported with orders
+		18	\| Independent reports = Submitted to this wiki by purchasers; see §Independent testing record
13	}}	19	}}
14	{{hatnote\|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}}	20	{{hatnote\|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}}
⋮		⋮
32		38
33	One documentation practice recorded across several reports is worth noting: certificates in this set have named the analytical method and column, which is uncommon. A purity figure with a stated method is more useful than one without, because [[Area percent purity\|area percent]] depends on the separation that produced it.{{r\|usp1503}}	39	One documentation practice recorded across several reports is worth noting: certificates in this set have named the analytical method and column, which is uncommon. A purity figure with a stated method is more useful than one without, because [[Area percent purity\|area percent]] depends on the separation that produced it.{{r\|usp1503}}
+		40
+		41	== Product range ==
+		42	\| Class \| Representative listings \| Documentation reported \|
+		43	\|---\|---\|---\|
+		44	\| Incretin analogues \| Semaglutide, tirzepatide, retatrutide \| Certificate with method, purity, water \|
+		45	\| Research peptides \| Repair and secretagogue peptides \| Certificate with method \|
+		46	\| SARMs \| Bulk \| Certificate, purity \|
+		47	\| Raw materials and oils \| Bulk \| Certificate with identity and purity; specification sheet on request \|
+		48
+		49	== Independent testing record ==
+		50	Submitted reports on KP material to July 2026 are concentrated on the incretin analogues. Reported [[Area percent purity\|area percent]] figures have clustered in the high nineties, and because the accompanying certificates named the method, several purchasers were able to run a comparable separation rather than a merely similar one.{{r\|reports}}
34		51
35	== References ==	52	== References ==